ACIU Projected Dividend Yield
Ord/AC Immune SA ( NASDAQ : ACIU )AC Immune is a clinical stage biopharmaceutical company focused on developing medicine for neurodegenerative diseases. Co.'s clinical stage product candidates include: ACI-35.030, which targets pathological Tau and is intended as a disease-modifying treatment for Alzheimer's disease (AD) and other Tauopathies; Semorinemab, which is designed to slow the prion-like propagation of Tau pathology; ACI-24, in which it owns the global rights to ACI-24 and it develops ACI-24 in-house for AD and Down syndrome-related AD; and diagnostic candidates, in which it continues to develop its complementary diagnostic product candidates for Tau, a-syn (with Life Molecular Imaging SA) and TDP-43. 20 YEAR PERFORMANCE RESULTS |
ACIU Dividend History Detail ACIU Dividend News ACIU Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |